businessneutral
The Deal-Making Circus: A Week of Mergers, Mayhem and Fashion Faux Pas
Tuesday, September 10, 2024
GSK is also facing some scrutiny over its new asthma drug depemokimab, which was shown to reduce serious attacks in trials but still needs regulatory approval before hitting the market with a potential $3.9 billion price tag.
And finally, Norfolk Southern's CEO Alan Shaw got called out for allegedly engaging in an inappropriate workplace relationship - eek! The company quickly launched an independent investigation into the claims of misconduct.
It seems like everyone has their hands in someone else's business these days! Will all these deals and drama play out or fall apart?
Actions
flag content